Shots:

• Indivumed to receive upfront from Evotec- for accessing Indivumed’s database “IndivuType” and both companies will jointly invest in data analysis- target identification- validation- and drug discovery. Evotec will be responsible for upcoming partnering for the program/platform
• The focus of the agreement is to develop precision therapies for CRC patients with the combination of Evotec’s bioinformatics analysis platform “PanHunter” with CRC cohort of Indivumed’s IndivuType  
• IndivuType is a multi-omics database for personalized cancer therapies that allows identification of the novel targets and biomarkers enabling break-through insights that lead to new cancer solutions

Ref: Evotec | Image: Twitter